Maintenance Therapy the ‘Biggest Breakthrough in Decades’ for Ovarian Cancer

September 15, 2022 1:54 pm

by Karen Blum

Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.

Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,

Read more

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

September 15, 2022 10:45 am

by Kristi Rosa

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

Maintenance treatment with niraparib (Zejula) produced a sustained and

Read more

Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials

September 9, 2022 10:37 am

by Mike Bassett

— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib

PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more

Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response

July 7, 2022 10:30 am

NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.

For Read more

FDA Approves Zejula for Advanced Ovarian Cancer Subset

October 23, 2019 3:30 pm

By Jessica Skarzynski

The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous Read more